These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25121475)

  • 1. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation.
    Orandi BJ; Zachary AA; Dagher NN; Bagnasco SM; Garonzik-Wang JM; Van Arendonk KJ; Gupta N; Lonze BE; Alachkar N; Kraus ES; Desai NM; Locke JE; Racusen LC; Segev DL; Montgomery RA
    Transplantation; 2014 Oct; 98(8):857-63. PubMed ID: 25121475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant.
    Stewart ZA; Collins TE; Schlueter AJ; Raife TI; Holanda DG; Nair R; Reed AI; Thomas CP
    Transplant Proc; 2012 Dec; 44(10):3033-6. PubMed ID: 23195021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post-kidney Transplantation: A Consecutive Series of 15 Cases.
    Tan EK; Bentall A; Dean PG; Shaheen MF; Stegall MD; Schinstock CA
    Transplantation; 2019 Nov; 103(11):2397-2404. PubMed ID: 30801549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Splenic Irradiation for the Treatment of Severe Antibody-Mediated Rejection.
    Orandi BJ; Lonze BE; Jackson A; Terezakis S; Kraus ES; Alachkar N; Bagnasco SM; Segev DL; Orens JB; Montgomery RA
    Am J Transplant; 2016 Oct; 16(10):3041-3045. PubMed ID: 27214874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient.
    Chehade H; Rotman S; Matter M; Girardin E; Aubert V; Pascual M
    Pediatrics; 2015 Feb; 135(2):e551-5. PubMed ID: 25624380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.
    Burbach M; Suberbielle C; Brochériou I; Ridel C; Mesnard L; Dahan K; Rondeau E; Hertig A
    Transplantation; 2014 Nov; 98(10):1056-9. PubMed ID: 24839895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports.
    Kocak B; Arpali E; Demiralp E; Yelken B; Karatas C; Gorcin S; Gorgulu N; Uzunalan M; Turkmen A; Kalayoglu M
    Transplant Proc; 2013 Apr; 45(3):1022-5. PubMed ID: 23622614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human leukocyte antigen-incompatible kidney transplantation after "desensitization"--hope and reality.
    Neumayer HH; Budde K; Liefeldt L
    Transplantation; 2014 Oct; 98(8):819-20. PubMed ID: 25073038
    [No Abstract]   [Full Text] [Related]  

  • 9. Upfront use of eculizumab to treat early acute antibody-mediated rejection after kidney allotransplantation and relevance for xenotransplantation.
    Schwotzer N; Paganetti G; Barchi M; Perrottet N; Aubert V; Sadallah S; Rotman S; Venetz JP; Matter M; Golshayan D; Pascual M
    Xenotransplantation; 2020 Jul; 27(4):e12630. PubMed ID: 32698246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial.
    Marks WH; Mamode N; Montgomery RA; Stegall MD; Ratner LE; Cornell LD; Rowshani AT; Colvin RB; Dain B; Boice JA; Glotz D;
    Am J Transplant; 2019 Oct; 19(10):2876-2888. PubMed ID: 30887675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale.
    Fehr T; Gaspert A
    Transpl Int; 2012 Jun; 25(6):623-32. PubMed ID: 22394269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of antibodies in kidney transplant].
    Ruffoni E; Seveso M; Marson P; Tison T; Cozzi E
    G Ital Nefrol; 2012; 29 Suppl 54():S54-60. PubMed ID: 22388831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing Eculizumab for Antibody-Mediated Rejection in Kidney Transplantation: A Case Report.
    Smith B; Kumar V; Mompoint-Williams D; Reed RD; MacLennan PA; Stegner K; Locke JE
    Transplant Proc; 2016 Nov; 48(9):3099-3105. PubMed ID: 27932156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody.
    Ghirardo G; Benetti E; Poli F; Vidal E; Della Vella M; Cozzi E; Murer L
    Pediatr Transplant; 2014 Feb; 18(1):E1-5. PubMed ID: 24266980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
    Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
    Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.
    Glotz D; Russ G; Rostaing L; Legendre C; Tufveson G; Chadban S; Grinyó J; Mamode N; Rigotti P; Couzi L; Büchler M; Sandrini S; Dain B; Garfield M; Ogawa M; Richard T; Marks WH;
    Am J Transplant; 2019 Oct; 19(10):2865-2875. PubMed ID: 31012541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection.
    Locke JE; Magro CM; Singer AL; Segev DL; Haas M; Hillel AT; King KE; Kraus E; Lees LM; Melancon JK; Stewart ZA; Warren DS; Zachary AA; Montgomery RA
    Am J Transplant; 2009 Jan; 9(1):231-5. PubMed ID: 18976298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.
    Stegall MD; Diwan T; Raghavaiah S; Cornell LD; Burns J; Dean PG; Cosio FG; Gandhi MJ; Kremers W; Gloor JM
    Am J Transplant; 2011 Nov; 11(11):2405-13. PubMed ID: 21942930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies.
    Schinstock CA; Bentall AJ; Smith BH; Cornell LD; Everly M; Gandhi MJ; Stegall MD
    Am J Transplant; 2019 Jun; 19(6):1671-1683. PubMed ID: 30412654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible live donor renal transplantation.
    Kayler LK; Farber JL; Colombe B; LaCava D; Friedewald JJ; Ratner LE
    Transpl Int; 2006 Feb; 19(2):128-39. PubMed ID: 16441362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.